The estimated Net Worth of Jan Mattsson is at least $5.25 million dollars as of 23 January 2023. Jan Mattsson owns over 197 units of Albireo Pharma Inc stock worth over $2,405,027 and over the last 8 years he sold ALBO stock worth over $1,441,585. In addition, he makes $1,404,280 as Chief Scientific Officer at Albireo Pharma Inc.
Jan has made over 9 trades of the Albireo Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 197 units of ALBO stock worth $8,629 on 23 January 2023.
The largest trade he's ever made was exercising 39,330 units of Albireo Pharma Inc stock on 1 March 2021 worth over $39,330. On average, Jan trades about 4,159 units every 89 days since 2016. As of 23 January 2023 he still owns at least 54,474 units of Albireo Pharma Inc stock.
You can see the complete history of Jan Mattsson stock trades at the bottom of the page.
Dr. Jan P. Mattsson Ph.D. is the Chief Scientific Officer of Albireo Pharma Inc. Dr. Mattsson has served as our Chief Scientific Officer since January 2019 and previously served as our Chief Operating Officer from November 2016 until January 2019. Dr. Mattsson is a co-founder of Albireo and has served as Chief Operating Officer of Albireo AB since February 2010, as Managing Director of Albireo AB since March 2008, as a director of Albireo AB since May 2008 and as Managing Director and a director of Elobix AB since November 2013. Previously, he served as Vice President of Operations of Albireo AB from February 2008 to February 2010, as Chief Operating Officer of Albireo Limited from February 2010 until November 2016, and as a director of Albireo Limited from February 2008 to April 2015. Prior to co-founding Albireo, Dr. Mattsson served as Associate Director at AstraZeneca. Dr. Mattsson holds a Bachelor's degree in Chemistry and a Ph.D. in Biochemistry from University of Gothenburg.
As the Chief Scientific Officer of Albireo Pharma Inc, the total compensation of Jan Mattsson at Albireo Pharma Inc is $1,404,280. There are 2 executives at Albireo Pharma Inc getting paid more, with Ronald Cooper having the highest compensation of $2,995,410.
Jan Mattsson is 60, he's been the Chief Scientific Officer of Albireo Pharma Inc since 2019. There are 6 older and 12 younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.
Jan's mailing address filed with the SEC is Ten Post Office Square, Boston, MA 02109, USA.
Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs et Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Inc executives and other stock owners filed with the SEC include: